Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
Condition(s):Hepatitis CLast Updated:April 22, 2016Unknown status
Hide Studies Not Open or Pending
Condition(s):Hepatitis CLast Updated:April 22, 2016Unknown status
Condition(s):Cirrhosis; Portal Vein ThrombosisLast Updated:August 15, 2018Unknown status
Condition(s):Nonalcoholic Fatty Liver Disease; NAFLD; Nonalcoholic SteatohepatitisLast Updated:October 28, 2020Terminated
Condition(s):Malignant Liver Disease; Major Liver ResectionLast Updated:November 1, 2021Terminated
Condition(s):Covert Hepatic EncephalopathyLast Updated:July 1, 2021Completed
Condition(s):Spontaneous Bacterial PeritonitisLast Updated:January 31, 2024Completed
Condition(s):IBSLast Updated:December 12, 2013Completed
Condition(s):HIV; Hepatitis CLast Updated:September 28, 2015Withdrawn
Condition(s):Hepatic EncephalopathyLast Updated:December 13, 2018Completed
Condition(s):DiverticulitisLast Updated:October 20, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.